Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1805MR)

This product GTTS-WQ1805MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1805MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5093MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ15284MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ10359MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ4433MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ4769MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ6417MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ1363MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ6401MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW